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Defibrillation Testing
Should the Paradigm Shift?*
N. A. Mark Estes III, MD
Boston, Massachusetts
In 3 decades of clinical use of the implantable cardioverter-
defibrillator (ICD), defibrillation threshold (DFT) testing
has remained an integral part of the implantation procedure.
The prevailing rationale for the routine evaluation of DFTs
has been to ensure appropriate sensing of ventricular fibril-
lation, system integrity, and effective defibrillation (1–3).
Early ICD systems using monophasic waveforms with
epicardial patches or transvenous leads were associated with
a substantial incidence of elevated DFTs, requiring addi-
tional intervention to ensure clinical efficacy (1–3). Techni-
cally, the DFT is a probabilistic phenomenon requiring
multiple shocks to determine with precision. Clinically, the
DFT is commonly approximated with 1 or more shocks to
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terminate induced ventricular fibrillation and ensure a safety
margin between the DFT and the maximum output of the
ICD. Inadequate safety margins of10 J between the DFT
and maximum ICD energy delivery have been associated
with worse clinical outcomes (3). Contemporary ICD sys-
tems using active cans, pectoralis pulse generators, biphasic
waveforms, and intravascular high-voltage leads have con-
siderably lowered the incidence of elevated DFTs (4–13).
The reliability of current ICD systems has led implanting
physicians to abandon the practice of routine testing of
defibrillation efficacy before hospital discharge and annually.
Observational studies also have noted an elimination of
DFT testing in one-third of initial implants and two-thirds
of replacements (14–16). Indeed, based on a growing body
of evidence, the clinical utility of the determination of
defibrillation efficacy during de novo implants has been
questioned (4–13). With this background, it is appropriate
to re-evaluate whether DFT testing still should be routinely
performed at the initial ICD insertion procedure.
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routine evaluation of DFTs at ICD insertion (1–3). The
prospective randomized trials demonstrating efficacy of
the ICD for primary and secondary prevention of sudden
death have required DFT testing. Evaluation of DFTs
allows verification of sensing, integrity of the high-voltage
system, and programming lower initial shock energy for
ventricular fibrillation at 10 J over the DFT (1–3). Testing
of defibrillation efficacy represent a historical standard of
care, and eliminating the DFT testing may present a
medical legal issue for the physician performing the implan-
tation (1–3). However, the evidence supporting continued
DFT testing is limited by the absence of a prospective
randomized trial with appropriate clinical outcomes.
The arguments and evidence against the determination of
the DFTs include the risks of major complications related to
the testing (1–18). Death, stroke, myocardial infarction, and
anesthesia-related complications related to DFT determina-
tion are reported in 1% of implants. However, registry and
observational data may under-report the frequency of compli-
cations. Inadequate safety margins with current ICDs are very
uncommon. Implant DFTs and safety margins have not been
shown to predict long-term mortality or first shock efficacy for
contemporary ICDs (1–18). Other cogent arguments have
been advanced against DFT testing (19).
Predictors of high DFTs with ICD systems include
ventricular dilation, increased left ventricular mass, severely
impaired left ventricular function, heart failure, young age,
increased body size, and single coil leads (4–7). Multiple
measures can be employed in an attempt to lower the DFT
and thereby increase the safety margin. These include lead
repositioning, reprogramming polarity, altering waveform
tilt, removing or adding a superior vena cava lead, adding a
subcutaneous array, or implanting an azygous vein high-
voltage lead. Given the probabilistic nature of the DFT and
the absence of conclusive evidence that the DFT predicts
clinical outcomes, some clinicians believe that the additional
risk of these interventions may not be justified.
In this issue of the Journal, Brignole et al. (20) report the
results of the SAFE-ICD (Safety of Two Strategies of ICD
Management at Implantation) study, which provides addi-
tional evidence regarding DFT testing at initial implant.
The investigators report results from a prospective observa-
tional study designed to evaluate the outcome of 2 strate-
gies: performing defibrillation testing (DT) versus not
performing defibrillation testing (DT) during de novo
ICD implants (20). The 41 participating Italian centers
continued their standard practices related to DFT testing for
the 2,120 consecutive patients undergoing initial ICD inser-
tion during a 1-year period (20). The primary endpoint, a
composite of severe complications at ICD implant and sudden
cardiac death or resuscitation, was not different in the 2 groups.
During the 2 years of follow-up, it was reached in 1.72% of the
DT patients and 1.02% of the DT patients, with no
difference on mortality (20). The authors conclude that event
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DFT testing has limited clinical relevance. The investigators
note that these data support the strategy of omitting DFT
during initial ICD implantation (20).
Although this study is important and adds additional
insights, as an observational rather than randomized trial it
does not provide conclusive evidence. The SAFE-ICD trial
is the largest study evaluating the strategy of initial ICD
implant with or without DFT testing (20). The multicenter
design, enrollment of almost all eligible patients consecu-
tively, and 2-year follow-up are strengths of the study (20).
However, the absence of randomization resulted in con-
founding differences in the clinical profiles of patients
enrolled in the 2 strategies (20). Patients undergoing DFT
testing had a lower rate of class III or class IV heart failure,
atrial fibrillation, higher ejection fraction, and less use of
diuretics and digoxin (20). The study was powered to detect
a difference in the 2 groups with the assumption that the
primary endpoint would be reached in 2.5% of patients (20).
With a lower than expected number of patients reaching
this endpoint due to a low incidence of sudden death,
ultimately, the study was underpowered to detect a differ-
ence in the 2 groups. It is noteworthy that 42% of ICDs
placed were for cardiac resynchronization therapy and
29% for secondary prevention. Only 33% of cardiac
resynchronization therapy ICDs and 37% of secondary
prevention devices had DFT testing performed. Many
prior observational studies have omitted DFT testing
selectively in de novo ICD implants placed for primary
prevention (3–18).
Although the SAFE-ICD study supports the paradigm
shift toward elimination of DFTs at initial implants, it does
not conclusively resolve the issue (20). The investigators
make a meaningful contribution to the collective evidence
that routine determination of DFTs has more risks than
benefits for many patients at the time of initial ICD
insertion (20). Indeed, the recently reported trends of
eliminating DFT testing reflect the growing recognition by
implanting physicians that routine DFT testing in selected
patients is of limited clinical value (9,15). However, as an
observational trial with the limitations noted, it does not
provide definitive evidence that omission of DFT determi-
nation in all de novo ICD implants is clinically justified.
More conclusive data are anticipated within 1 year from the
results of a multicenter prospective trial that completed
randomization of 2,500 patients in April 2011 to DFT
testing versus no DFT determination (21). It is evident that
the paradigm should not yet shift to elimination of DFT
testing in all patients until more conclusive evidence is
available. The safety of using this approach for high-risk
patients remains unknown. In the meantime, implanting
physicians will have to decide on the basis of the best
available data, their experience, and judgment whether to
omit DFT testing selectively in lower-risk patients. dReprint requests and correspondence: Dr. N. A. Mark Estes III,
Tufts University School of Medicine, 860 Washington Street, Bos-
ton, Massachusetts 02493. E-mail: nestes@tuftsmedicalcenter.org.
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